Medtronic closes $816M buyout of Chinese devicemaker

Medtronic ($MDT) has closed the book on its $816 million acquisition of China's Kanghui Holdings, locking down shareholder approval for its buy of the orthopedics company.

The company has a longstanding goal of getting 20% of its revenue from emerging markets by 2016, and absorbing Kanghui's portfolio of trauma, spine and joint-reconstruction devices will help Medtronic become a leading force in China, Vice President Chris O'Connell said.

"The integration of Kanghui provides Medtronic a strong position in China's rapidly expanding orthopedics segment, as well as a high potential platform for development of a global value segment in orthopedics," O'Connell said in a statement.

The Kanghui buy is Medtronic's largest Chinese acquisition, but it's not the only one. Earlier this month, the company spent $66.2M for a stake in Shenzhen's LifeTech Scientific and in 2011 launched a joint venture with Shandong Weigao. Medtronic has stepped up its Chinese interests of late, joining Johnson & Johnson ($JNJ), Covidien ($COV) and others in opening R&D facilities in the country.

For years, devicemakers approached the fast-growing Chinese market by trying to port U.S. techs overseas, often struggling to find buyers in the comparatively cash-strapped environment. Recently, however, the industry giants have looked to partner with--or buy outright--local firms, using in-country know-how to develop devices better suited for China's hospitals and reimbursement structures.

- read Medtronic's release

Suggested Articles

Johnson & Johnson Vision announced that the worldwide president of its surgical business, Tom Frinzi, plans to retire at the end of this year.

Philips looked back on 15 years of data from one of its telehealth-equipped intensive care units, where centralizing operations reduced mortality.

Sanofi will look to pull back from its three-year-old relationship with Verily and their virtual diabetes clinic, Onduo.